Trospium Chloride Tablet, Film Coated
Product Images NDC 71335-2961

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 71335-2961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A pharmacokinetic curve showing plasma concentration (ng/mL) of a drug plotted against time (hours post-dose) over a 48-hour period. The graph displays data points with error bars, indicating concentration variability, with a peak around 2-4 hours post-dose followed by a gradual decline.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph comparing the mean change over weeks of treatment between placebo and Trospium Chloride tablets groups. The x-axis represents weeks of treatment (1, 4, 12), and the y-axis shows mean change with standard error. Trospium Chloride group shows a greater decrease compared to placebo at each time point, with p-values indicating statistical significance.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph comparing mean changes over weeks of treatment between placebo and Trospium Chloride tablets (20 mg). The x-axis shows treatment weeks (1, 4, 12), and the y-axis shows mean change with standard error. Both groups start near zero, with Trospium Chloride showing a larger decrease over time. P-values at weeks 4 and 12 indicate statistical significance.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing mean ± standard error changes over 12 weeks of treatment for placebo and Trospium Chloride tablets. The x-axis shows weeks of treatment (1, 4, and 12), while the y-axis indicates mean change, with Trospium Chloride showing a greater decrease compared to placebo. Sample sizes are 323 for Trospium Chloride and 325 for placebo.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph comparing mean change over treatment weeks between placebo and TROSPIUM CHLORIDE tablets groups. The x-axis represents weeks of treatment (1, 4, 12), and the y-axis shows mean change with standard error. The TROSPIUM CHLORIDE group shows a greater negative mean change over time than placebo.*
FDA Label Image

Chemical Structure (Image 01)

Chemical Structure (Image 01)
Chemical structure of TROSPIUM CHLORIDE, showing its molecular framework with bicyclic and quaternary ammonium components, along with phenyl groups and a carboxylate linkage.*
FDA Label Image

Label (Lbl713352961)

Label (Lbl713352961)
Trosium Chloride Tablets 20 mg film-coated tablet label showing dosage strength and NDC 71335-2961-1. The label indicates repackaging by Bryant Ranch Prepack, Inc., Burbank, CA, and manufacturing by Padagis. The package contains 60 tablets and includes storage instructions and safety warnings. Two QR codes are present, one for GTIN and another for the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.